Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmbetter Nevada Inlexzo Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedAmbetter NevadaPolicy CP.PHAR.753

    Gemcitabine Intravesical System (Inlexzo)

    Customize your policy alerts

    Sign up for Ambetter Nevada Policy CP.PHAR.753 alerts

    Get alerted when Policy CP.PHAR.753 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Inlexzo in adult members with BCG-unresponsive non-muscle invasive bladder cancer and other requested indications. It applies to Commercial, HIM/ICHRA, and Medicaid lines of business.

    Policy Summary
    PayerAmbetter Nevada
    PolicyGemcitabine Intravesical System (Inlexzo)
    Policy CodePolicy CP.PHAR.753
    Change TypeModified
    Effective DateDec 1, 2025
    Last ReviewNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit clinical documentation showing that all initial approval criteria are met, including diagnosis, specialist involvement, age, BCG-refractory disease, cystectomy ineligibility, prior TURBT, and an approved or adequately supported regimen.
    SourceLink
    POLICY UPDATE CHANGES

    The 2026 annual review added coverage criteria for NMIBC with Ta or T1 papillary tumors in accordance with NCCN recommendations.

    HCPCS code J9183 was added for gemcitabine intravesical system, 225 mg.

    HCPCS codes J3590 and C9399 were removed from the coding references.

    The annual review added the ICHRA line of business.

    The policy added an option for use in non-muscle-invasive bladder cancer with Ta or T1 papillary tumors consistent with NCCN guidance.

    References were reviewed and updated during the annual policy review.

    225 mgSingle-dose system strength
    8 + 6

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Labeled instillation schedule
    12 monthsApproval duration
    <14Continuation limit
    J9183Current HCPCS code